Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

• Status: Unknown status
• Trial end date: 2021-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin together with etoposide and methylprednisolone as a induction therapy for lymphoma induced hemophagocytic lymphohistiocytosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Friendship Hospital
• Treatments: Doxorubicin; Etoposide; Liposomal doxorubicin; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• 1.Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.

• 2.Patients were older than 2 years of age.

• 3.Estimated survival time ≥ 1 week.

• 4.Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index >250.

• 5.sign informed consent.

Exclusion Criteria:

• 1.Heart function above grade II (NYHA).

• 2.Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease.

• 3.Pregnancy or lactating Women.

• 4.Allergic to pegylated liposomal doxorubicin or etoposide.

• 5.Active bleeding of the internal organs.

• 6.HIV antibody positivity.

• 7.Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable).

• 8.Participate in other clinical research at the same time.

• 9.The researchers considered that patients are not suitable for the study.